| 15.58 0.32 (2.1%) | 10-15 12:13 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.62 |
1-year : | 22.91 |
| Resists | First : | 16.79 |
Second : | 19.62 |
| Pivot price | 15.52 |
|||
| Supports | First : | 14.96 |
Second : | 13.82 |
| MAs | MA(5) : | 15.35  |
MA(20) : | 15.45 |
| MA(100) : | 16.97 |
MA(250) : | 25.08 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 42 |
D(3) : | 35.6 |
| RSI | RSI(14): 53.6 |
|||
| 52-week | High : | 37.66 | Low : | 12.39 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SLP ] has closed below upper band by 45.3%. Bollinger Bands are 53.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 52 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 15.7 - 15.79 | 15.79 - 15.86 |
| Low: | 14.82 - 14.95 | 14.95 - 15.04 |
| Close: | 15.08 - 15.26 | 15.26 - 15.41 |
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Wed, 15 Oct 2025
Simulations Plus (SLP) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Sun, 12 Oct 2025
SLP Investor News: If You Have Suffered Losses in - GlobeNewswire
Fri, 10 Oct 2025
SLP SECURITIES NOTICE: Simulations Plus, Inc. Securities - GlobeNewswire
Thu, 09 Oct 2025
Simulations Plus, Inc. (NASDAQ:SLP) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Tue, 30 Sep 2025
TD Cowen Initiates Coverage of Simulations Plus (SLP) with Hold Recommendation - Nasdaq
Mon, 22 Sep 2025
The Bottom Fishing Club - Simulations Plus: Huge Potential In AI Drug Discovery - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 20 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 17.2 (%) |
| Held by Institutions | 85.4 (%) |
| Shares Short | 1,170 (K) |
| Shares Short P.Month | 1,620 (K) |
| EPS | -3.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.15 |
| Profit Margin | -78.7 % |
| Operating Margin | 18.1 % |
| Return on Assets (ttm) | 2.7 % |
| Return on Equity (ttm) | -41.5 % |
| Qtrly Rev. Growth | 9.8 % |
| Gross Profit (p.s.) | 2.14 |
| Sales Per Share | 3.99 |
| EBITDA (p.s.) | 0.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 14 (M) |
| Levered Free Cash Flow | 9 (M) |
| PE Ratio | -4.97 |
| PEG Ratio | 0 |
| Price to Book value | 2.54 |
| Price to Sales | 3.91 |
| Price to Cash Flow | 22.17 |
| Dividend | 0.05 |
| Forward Dividend | 0 |
| Dividend Yield | 0.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|